Trial reportPloS one2026
Clinical outcomes of hyaluronic acid-sorbitol injection in athletes with patellofemoral pain: Evaluation of the potential influence of body mass index.
Trial report in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05450458 (Safety and Effectiveness of Hyaluronic Acid and Sorbitol With Overuse Knee Pain in Sportsmen), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Safety and Effectiveness of Hyaluronic Acid and Sorbitol With Overuse Knee Pain in Sportsmen
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPatellofemoral pain (PFP) is a frequent cause of activity-related knee pain and functional limitation in athletic populations. Elevated body mass index (BMI) may contribute to patellofemoral joint loading, but evidence on hyaluronic acid-sorbitol injection outcomes in athletes with elevated BMI remains limited.
objectiveTo describe longitudinal changes in knee function and symptoms over 6 months after intra-articular hyaluronic acid-sorbitol injection in athletes with PFP, and to explore whether baseline BMI was associated with post-injection improvement.
methodsThis prospective, single-arm, non-randomized interventional study included 60 athletes aged 30-55 years who received a single 4 mL intra-articular hyaluronic acid-sorbitol injection. IKDC and KOOS scores were assessed at baseline, 15 days, 3 months, and 6 months. Longitudinal changes were evaluated using linear mixed models, with generalized estimating equations as a sensitivity analysis; exploratory regression and subgroup analyses assessed the association between BMI and improvement.
resultsMean IKDC and KOOS scores increased from baseline to 6 months, with estimated changes of +18.58 points for IKDC (95% CI 16.81-20.36) and +19.28 points for KOOS (95% CI 17.52-21.04; both p < 0.001). At 6 months, 75.0% of participants reached the predefined IKDC threshold for clinically meaningful improvement and 83.3% reached the KOOS threshold. Participants with BMI ≥ 25 kg/m2 also showed within-group improvement. BMI was not independently associated with improvement rate after adjustment for baseline score; however, the small elevated-BMI subgroup (n = 22) limited these exploratory comparisons, and a clinically relevant difference could not be excluded. Minor local adverse events occurred in 4 of 60 participants and resolved with cryotherapy.
conclusionAthletes with PFP, including those with elevated BMI, showed consistent improvement in knee function and symptoms over 6 months following hyaluronic acid-sorbitol injection. These findings support intra-articular hyaluronic acid-sorbitol as a feasible, well-tolerated option for athletes with PFP, regardless of body weight. Controlled trials are needed to confirm the treatment's contribution, given the single-arm design.
trial registrationCEI/0504/PI/2022; ClinicalTrials.gov NCT05450458.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.